Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,283.40 +5.89 (+0.11%) Dow
38,571.03 -115.29 (-0.30%) Nasdaq
16,828.67 +93.65 (+0.56%) Bitcoin USD
69,393.62 +1,725.66 (+2.55%) CMC Crypto 200
1,452.27 -15.66 (-1.07%)
Microbot Medical Inc. (MBOT)
After hours:
| Previous close | 1.0000 |
| Open | 1.2100 |
| Bid | 1.3300 x 100 |
| Ask | 1.3800 x 200 |
| Day's range | 1.2000 - 2.3499 |
| 52-week range | 0.8600 - 3.6600 |
| Volume | |
| Avg. volume | 95,836 |
| Market cap | 19.871M |
| Beta (5Y monthly) | 1.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8700 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.00 |
GlobeNewswireMicrobot Medical Announces $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
HINGHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 1,566,669 shares of the Company’s common stock at a purchase price of $1.50 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered series F preferred investment options. The series F preferred
- GlobeNewswire
Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial
The trial will be conducted in the U.S. and its results will complement the preclinical data on the LIBERTY® Endovascular Robotic Surgical System, which together are expected to support a future 510(k) submissionBRAINTREE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces that it has received the U.S. Food and Drug Administration’s (“FDA”) approval to proceed with its pivotal h
- GlobeNewswire
Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™
The next step of the collaboration will explore potential future applications of the LIBERTY system, including its potential capabilities for remote endovascular proceduresBRAINTREE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today reports that the first phase of the previously announced collaboration with Corewell Health has been completed, which demonstrated the LIBERTY® System's tec
